Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Observational Study of the Response to Rituximab (MabThera®) in Seropositive Patients With Rheumatoid Arthritis With Inadequate Response or Intolerance to Treatment With One or More Tumor Necrosis Factor Inhibitors (TNFi)

NCT01613027 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01613027
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01613027 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Observational Study of the Response to Rituximab (MabThera®) in Seropositive Patients With Rheumatoid Arthritis With Inadequate Response or Intolerance to Treatment With One or More Tumor Necrosis Factor Inhibitors (TNFi)
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Completed
Start date
February 29, 2012
Completion date
September 30, 2015
Enrollment
135 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis